- Drugs
- Tuesday, 17 Sep 2019
Aphria Inc.'s Jamaican Subsidiary, Marigold, Receives Retail Herb House Licence
Aphria Inc. announced that its subsidiary Marigold Projects Jamaica Limited ("Marigold") has received a retail Herb House license from Jamaica's Cannabis Licensing Authority ("CLA") to open its first store in Kingston, Jamaica.
Aphria, Inc. is engaged in the production and supply of medical cannabis. It operates through three reportable segments including cannabis operations, distribution operations, and business under development. The Cannabis Operations segment produces, distributes, and sells both medical and adult-use cannabis. The Distribution Operations segment are carried out through its wholly owned subsidiaries ABP, FL Group, and CC Pharma. The Distribution under Development segment includes operations in which the firm has not received final licensing or has not commenced commercial sales from operations. The company offers medical cannabis of various strains, including Kusawa, Tamaracouta, Panache, Churchill and Iroquois. The Company is also engaged in the research and development, and commercial production of cannabis oil. The company was founded by Cole Cacciavillani and John Cervini on June 22, 2011 and is headquartered in Leamington, Canada. Aphria’s subsidiaries include Pure Natures Wellness Inc. that are engaged in the production and distribution of medical marijuana, and Cannway Pharmaceuticals Ltd., which specializes in offering support services to veterans and their first responders.
Related Industry Updates
US Mail Order Pharmacy Market is expected to reach US$ 1,71,883.03 million by 2030
Oct 16, 2023
Hospital Acquired Infection Treatment Market is expected to reach US$ 19,978.39 million by 2030
Dec 11, 2023
Ion Channel Modulators Market - Segmentation, Manufacturing Cost Analysis Including Key Raw Materials, Price Trend, Key Suppliers and Forecast 2027
Mar 09, 2021
Clinical Trial Imaging Market is expected to reach US$ 2,480.32 million by 2028
May 23, 2023
Sanofi says COVID-19 vaccine will be available globally at the same time
May 15, 2020
Sickle Cell Disease Treatment Market is expected to reach US$ 4,691.87 million by 2030
Nov 07, 2023
Nasal Polyps Treatment Market Size will Escalate Rapidly in the Near Future 2020: Forecast 2027 by OptiNose US, Inc. , Regeneron Pharmaceuticals, Inc. , Merck KGaA , Pfizer, Inc.
Apr 09, 2021